Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 2
2007 1
2009 1
2012 2
2015 1
2016 1
2017 1
2018 2
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.
Borgatti A, Koopmeiners JS, Sarver AL, Winter AL, Stuebner K, Todhunter D, Rizzardi AE, Henriksen JC, Schmechel S, Forster CL, Kim JH, Froelich J, Walz J, Henson MS, Breen M, Lindblad-Toh K, Oh F, Pilbeam K, Modiano JF, Vallera DA. Borgatti A, et al. Among authors: Todhunter D. Mol Cancer Ther. 2017 May;16(5):956-965. doi: 10.1158/1535-7163.MCT-16-0637. Epub 2017 Feb 13. Mol Cancer Ther. 2017. PMID: 28193671 Free PMC article.
Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma.
Borgatti A, Fieberg A, Winter AL, Stuebner K, Taras E, Todhunter D, Masyr A, Rendhal A, Vallera DA, Koopmeiners JS, Modiano JF. Borgatti A, et al. Among authors: Todhunter D. Vet Comp Oncol. 2020 Mar 18. doi: 10.1111/vco.12590. Online ahead of print. Vet Comp Oncol. 2020. PMID: 32187827
Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS. Gleason MK, et al. Among authors: Todhunter DA. Mol Cancer Ther. 2012 Dec;11(12):2674-84. doi: 10.1158/1535-7163.MCT-12-0692. Epub 2012 Oct 17. Mol Cancer Ther. 2012. PMID: 23075808 Free PMC article.
16 results
Jump to page
Feedback